Cardiovascular Disease
Cardiovascular disease is the number one cause of death in the United States. (Centers for Disease Control and Prevention)
More than 800,000 deaths each year are caused by cardiovascular disease. (Centers for Disease Control and Prevention, 2021)
An estimated $320 billion in healthcare costs and lost productivity annually is attributed to cardiovascular disease. (Centers for Disease Control and Prevention)
2023 PCORI Annual Meeting Breakout Session Spotlight
Database Identifies Emerging Technologies, Innovations
PCORI’s Horizon Scanning Database offers healthcare decision makers findings about advancements in six key areas of interest: Alzheimer’s disease and other dementias, cancer, cardiovascular diseases, COVID-19, mental and behavioral health, and rare diseases. This database can be used by patients, care partners, and others to track advancements in care options.
Study Results that Support Better-Informed Decisions
Aspirin Dosing Study Highlights Benefits, Effectiveness for People with Heart Disease
People with cardiovascular disease who took aspirin to lower their chances of having a heart attack or stroke experienced similar health benefits, including reduced death and hospitalization for heart attack and stroke, whether they took a high or low dose of aspirin, according to findings from the PCORI-funded ADAPTABLE Study, the largest aspirin dosing trial conducted in routine care and clinical settings.
The results were presented at ACC.21 – the American College of Cardiology’s 70th Annual Scientific Session – and simultaneously published in the New England Journal of Medicine on May 15, 2021.
Evidence for Decisions from PCORI-Funded Studies
Evidence Updates: Reducing Risk of Stroke in Patients with Atrial Fibrillation
People with atrial fibrillation (AFib) have a higher risk for stroke compared with people who have a normal heart rhythm. Medicines that keep blood from clotting, called anticoagulants, lower the risk of stroke but can also cause serious bleeding.
A recent review of research found that some newer anticoagulants do better at reducing the risk of stroke, and some also reduce the risk of serious bleeding compared to traditional therapies.